



Docket No.  
57155-AA

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Christophe P.G. Gerald, et al. Group Art Unit: 1646

Application No.: 09/866,248 Examiner: Joseph F. Murphy

Filed: May 25, 2001

For: DNA ENCODING MAMMALIAN NEUROPEPTIDE FF (NPFF)  
RECEPTORS AND USES THEREOF

Date: October 13, 2004

**CERTIFICATE OF MAILING  
BY "FIRST CLASS MAIL" (37 C.F.R. § 1.8)**

Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

I hereby certify that the following correspondence:

Fee Transmittal for FY 2005 (PTO/SB/17); Amendment In Response To September 2, 2004 Office Action and Supplemental Information Disclosure Statement (14 pgs); Information Disclosure Statement by Applicant (PTO/SB/08a) (1pg); Copy of U.S. Serial No. 09/538,036; and Check (\$180.00)

is being deposited on October 13, 2004 with the United States Postal Service as first class mail in an envelope bearing sufficient postage thereon and addressed to:

**Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450.**

**Mary Johnson**

(Typed Or Printed Name Of Person Mailing Correspondence)

  
(Signature Of Person Mailing Correspondence)

OCT 15 2004

PTO/SB/17 (10-04)

Approved for use through 07/31/2006. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL  
for FY 2005**

Effective 10/01/2004. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00)

## Complete if Known

Application Number	09/866,248
Filing Date	May 25, 2001
First Named Inventor	Christophe P.G. Gerald
Examiner Name	J. F. Murphy
Art Unit	1646
Attorney Docket No.	57155-AA

## METHOD OF PAYMENT (check all that apply)

 Check    Credit card    Money Order    Other    None
 Deposit Account:

Deposit Account Number  
503201  
Deposit Account Name  
Synaptic Pharmaceutical Corp.

The Director is authorized to: (check all that apply)

- Charge fee(s) indicated below    Credit any overpayments  
 Charge any additional fee(s) or any underpayment of fee(s)  
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

## 1. BASIC FILING FEE

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code (\$)	Fee Code (\$)		
1001 790	2001 395	Utility filing fee	
1002 350	2002 175	Design filing fee	
1003 550	2003 275	Plant filing fee	
1004 790	2004 395	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
<b>SUBTOTAL (1)</b>		<b>(\$ 0.00)</b>	

## 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims	Fee from below	Fee Paid
Total Claims		-20** =		= 0
Independent Claims		- 3*** =		= 0
Multiple Dependent				

Large Entity	Small Entity	Fee Description
Fee Code (\$)	Fee Code (\$)	
1202 18	2202 9	Claims in excess of 20
1201 88	2201 44	Independent claims in excess of 3
1203 300	2203 150	Multiple dependent claim, if not paid
1204 88	2204 44	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent
<b>SUBTOTAL (2)</b>		<b>(\$ 0.00)</b>

\*\*or number previously paid, if greater; For Reissues, see above

## 3. ADDITIONAL FEES

Large Entity   Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 430	2252 215	Extension for reply within second month	
1253 980	2253 490	Extension for reply within third month	
1254 1,530	2254 765	Extension for reply within fourth month	
1255 2,080	2255 1,040	Extension for reply within fifth month	
1401 340	2401 170	Notice of Appeal	
1402 340	2402 170	Filing a brief in support of an appeal	
1403 300	2403 150	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,370	2501 685	Utility issue fee (or reissue)	
1502 490	2502 245	Design issue fee	
1503 660	2503 330	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	180
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 790	2809 395	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 790	2810 395	For each additional invention to be examined (37 CFR 1.129(b))	
1801 790	2801 395	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	
Other fee (specify) _____			

\*Reduced by Basic Filing Fee Paid

**SUBTOTAL (3) (\$ 180.00)**

## SUBMITTED BY

(Complete if applicable)

Name (Print/Type)	Stephen G. Kalinchak	Registration No. (Attomey/Agent)	38,747	Telephone (201) 261-1331
Signature	<i>Stephen G. Kalinchak</i>		Date	October 13, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Dkt. 57155-AA

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Christophe P.G. Gerald, et al.  
Serial No.: 09/866,248 Examiner: J. F. Murphy  
Filed: May 25, 2001 Group Art Unit: 1646  
For: DNA ENCODING MAMMALIAN NEUROPEPTIDE FF (NPFF)  
RECEPTORS AND USES THEREOF

215 College Road  
Paramus, New Jersey  
October 13, 2004

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**AMENDMENT IN RESPONSE TO SEPTEMBER 2, 2004 OFFICE ACTION AND**  
**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

This Amendment is submitted in response to the September 2, 2004 Office Action issued in connection with the above-identified application. A response to the September 2, 2004 Office Action is due December 2, 2004. Accordingly, this Amendment is being timely filed.

In response to the September 2, 2004 Office Action, please amend the subject application as follows:

**Amendments to the Claims** are reflected in the listing of claims 1-191 which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 12 of this paper.

**Supplemental Information Disclosure Statement** begins on page 13 of this paper.